Design Therapeutics Inc (DSGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 298,569 | 357,662 | 370,838 | 400,693 | 2,379 |
| Marketable Securities | 85,495 | 36,056 | 31,998 | 10,646 | 33,712 |
| TOTAL | $385,435 | $395,290 | $404,875 | $411,754 | $36,233 |
| Non-Current Assets | |||||
| PPE Net | 1,508 | 1,320 | 271 | 100 | 71 |
| Other Non-Current Assets | 3,614 | 3,743 | 0 | 0 | 212 |
| TOTAL | $5,122 | $5,063 | $271 | $100 | $283 |
| Total Assets | $390,557 | $400,353 | $405,146 | $411,854 | $36,516 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,620 | 2,216 | 1,585 | 2,033 | 1,399 |
| Accrued Expenses | 3,663 | 3,289 | 1,820 | 1,673 | 931 |
| TOTAL | $5,283 | $5,505 | $3,405 | $3,706 | $2,330 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 3,144 | 3,284 | 140 | 142 | 45,501 |
| TOTAL | $3,144 | $3,284 | $140 | $142 | $45,501 |
| Total Liabilities | $8,427 | $8,789 | $3,545 | $3,848 | $47,831 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 55,700 | 55,663 | 55,617 | 55,617 | N/A |
| Common Shares | 6 | 6 | 6 | 6 | 1 |
| Retained earnings | -47,456 | -36,391 | -25,073 | -17,437 | -11,923 |
| Other shareholders' equity | -244 | -4 | -12 | 2 | 156 |
| TOTAL | $382,130 | $391,564 | $401,601 | $408,006 | $-11,315 |
| Total Liabilities And Equity | $390,557 | $400,353 | $405,146 | $411,854 | $36,516 |